Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)WithdrawnNCT04756505
What this trial is testing

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast AdenocarcinomaMetastatic Breast Carcinoma+2 more
M.D. Anderson Cancer Center
Not applicableEnded earlyNCT04370522
What this trial is testing

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Spanish Breast Cancer Research Group 32
Testing effectiveness (Phase 2)Looking for participantsNCT06938724
What this trial is testing

Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer

Who this might be right for
Breast Neoplasm Malignant Female
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 152
Early research (Phase 1)WithdrawnNCT04142554
What this trial is testing

Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsTriple Negative Breast Cancer+1 more
UNC Lineberger Comprehensive Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03568422
What this trial is testing

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Canadian Cancer Trials Group 37
Not applicableUnknownNCT04030728
What this trial is testing

Implementing Patients´ Competence in Oral Breast Cancer Therapy

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Onco Medical Consult GmbH 212
Testing effectiveness (Phase 2)Study completedNCT03227328
What this trial is testing

CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Who this might be right for
Hormone Receptor Positive Breast CancerMetastatic Breast CancerHormone Receptor Negative Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Not applicableEnded earlyNCT06126003
What this trial is testing

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Who this might be right for
Breast Cancer
BioCorteX Inc 2
Testing effectiveness (Phase 2)Ended earlyNCT00827567
What this trial is testing

Trial of RAD001 in Triple Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Milton S. Hershey Medical Center 6
Large-scale testing (Phase 3)UnknownNCT01917279
What this trial is testing

Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC

Who this might be right for
Breast NeoplasmsNeoplasms by SiteNeoplasm Metastasis+2 more
Binghe Xu 280
Testing effectiveness (Phase 2)Looking for participantsNCT05576389
What this trial is testing

Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study

Who this might be right for
Germline BRCA-mutated HER2-negative Breast Cancer
Peking University People's Hospital 64
Post-approval studies (Phase 4)Looking for participantsNCT05362760
What this trial is testing

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

Who this might be right for
Hormone Receptor-positive Metastatic Breast CancerHER2-negative Metastatic Breast Cancer
Prof. Wolfgang Janni 300
Testing effectiveness (Phase 2)UnknownNCT06133088
What this trial is testing

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Who this might be right for
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
Zhejiang Cancer Hospital 53
Testing effectiveness (Phase 2)Looking for participantsNCT07647016
What this trial is testing

Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study

Who this might be right for
Breast Cancer
Fudan University 53
Testing effectiveness (Phase 2)Study completedNCT00834678
What this trial is testing

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Who this might be right for
Breast Cancer
Ohio State University Comprehensive Cancer Center 11
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Testing effectiveness (Phase 2)Ended earlyNCT01022138
What this trial is testing

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Barbara Ann Karmanos Cancer Institute 43
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Testing effectiveness (Phase 2)WithdrawnNCT01100489
What this trial is testing

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Who this might be right for
Ductal Breast Carcinoma in SituEstrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast Cancer+13 more
Case Comprehensive Cancer Center
Next Page